



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Tipifarnib

Item No. 11747

CAS Registry No.: 192185-72-1
Formal Name: 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
Synonym: R 115777
MF: C₂₇H₂₂Cl₂N₄O
FW: 489.4
Purity: ≥98%
UV/Vis.: λ_{max}: 237, 285, 340 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tipifarnib is supplied as a crystalline solid. A stock solution may be made by dissolving the tipifarnib in the solvent of choice. Tipifarnib is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas. The solubility of tipifarnib in these solvents is approximately 5 and 10 mg/ml, respectively.

Description

Tipifarnib is a nonpeptidomimetic, CAAX-competitive inhibitor of farnesyltransferase (IC₅₀ = 0.86 nM).¹ It prevents farnesylation of Ras GTPases and has shown potent efficacy in various *in vitro* and *in vivo* tumor models.^{2,3}

References

1. Bell, I.M. Inhibitors of farnesyltransferase: A rational approach to cancer chemotherapy? *J. Med. Chem.* **47**(8), 1869-1878 (2004).
2. Vigil, D., Cherfils, J., Rossman, K.L., et al. Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? *Nat. Rev. Cancer* **10**(12), 842-857 (2010).
3. Appels, N.M.G.M., Beijnen, J.H., and Schellens, J.H.M. Development of farnesyl transferase inhibitors: A review. *Oncologist* **10**, 565-578 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM